Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Electrozinc shareholders to discuss the company's liquidation

10/5/23 ELTZ

Novabev Group shipments for 9 months decreased by 1.2%

10/5/23 BELU

Astra Group announced the IPO price range

10/5/23 ASTR

VK game engine has collected several thousand applications for tests from game studios

10/5/23 VKCO

Polymetal will start launching AGMK-2 by the end of summer 2024

10/5/23 POLY

McDonald's announced a quarterly dividend

10/5/23 MCD

Albert Avdolyan has attracted a new partner to YATEK

10/5/23 YAKG

Pfizer announced a quarterly dividend

10/5/23 PFE

Sollers' sales in Russia for 9 months increased by 39.2%

10/4/23 SVAV

Gold Bear has been redomiciled to Russia under the name Headhunter

10/4/23 HEAD